Enzyme replacement therapy is the only therapeutic option for Fabry patients with completely absent AGAL activity. However, the treatment has side effects, is costly, and requires conspicuous amounts of recombinant human protein (rh-AGAL). Thus, its optimization would benefit patients and welfare/health services (i.e., society at large). In this brief report, we describe preliminary results paving the way for two possible approaches: i. the combination of enzyme replacement therapy with pharmacological chaperones; and ii. the identification of AGAL interactors as possible therapeutic targets on which to act. We first showed that galactose, a low-affinity pharmacological chaperone, can prolong AGAL half-life in patient-derived cells treated with rh-AGAL. Then, we analyzed the interactomes of intracellular AGAL on patient-derived AGAL-defective fibroblasts treated with the two rh-AGALs approved for therapeutic purposes and compared the obtained interactomes to the one associated with endogenously produced AGAL (data available as PXD039168 on ProteomeXchange). Common interactors were aggregated and screened for sensitivity to known drugs. Such an interactor-drug list represents a starting point to deeply screen approved drugs and identify those that can affect (positively or negatively) enzyme replacement therapy.

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy / Iacobucci, Ilaria; Hay Mele, Bruno; Cozzolino, Flora; Monaco, Vittoria; Cimmaruta, Chiara; Monti, Maria; Andreotti, Giuseppina; Monticelli, Maria. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:5(2023), p. 4548. [10.3390/ijms24054548]

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy

Iacobucci, Ilaria
Co-primo
;
Hay Mele, Bruno
Co-primo
;
Cozzolino, Flora;Monaco, Vittoria;Monti, Maria
;
Andreotti, Giuseppina
Penultimo
;
Monticelli, Maria
Ultimo
2023

Abstract

Enzyme replacement therapy is the only therapeutic option for Fabry patients with completely absent AGAL activity. However, the treatment has side effects, is costly, and requires conspicuous amounts of recombinant human protein (rh-AGAL). Thus, its optimization would benefit patients and welfare/health services (i.e., society at large). In this brief report, we describe preliminary results paving the way for two possible approaches: i. the combination of enzyme replacement therapy with pharmacological chaperones; and ii. the identification of AGAL interactors as possible therapeutic targets on which to act. We first showed that galactose, a low-affinity pharmacological chaperone, can prolong AGAL half-life in patient-derived cells treated with rh-AGAL. Then, we analyzed the interactomes of intracellular AGAL on patient-derived AGAL-defective fibroblasts treated with the two rh-AGALs approved for therapeutic purposes and compared the obtained interactomes to the one associated with endogenously produced AGAL (data available as PXD039168 on ProteomeXchange). Common interactors were aggregated and screened for sensitivity to known drugs. Such an interactor-drug list represents a starting point to deeply screen approved drugs and identify those that can affect (positively or negatively) enzyme replacement therapy.
2023
Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy / Iacobucci, Ilaria; Hay Mele, Bruno; Cozzolino, Flora; Monaco, Vittoria; Cimmaruta, Chiara; Monti, Maria; Andreotti, Giuseppina; Monticelli, Maria. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:5(2023), p. 4548. [10.3390/ijms24054548]
File in questo prodotto:
File Dimensione Formato  
ijms-24-04548.pdf

accesso aperto

Descrizione: Final version
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.36 MB
Formato Adobe PDF
1.36 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/913399
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact